Clinical Trials

351 enrolled

Stomach Neoplasms

NCT04559607 2023-12-18

TACE Combined With Camrelizumab and Apatinib in Intermediate and Advanced Hepatocelluar Carcinoma

188 enrolled

Carcinoma, Hepatocellular

NCT06140732 2023-11-20

Apatinib Combined With Camrelizumab in Treating Participants With Advanced Chordoma

30 enrolled

Chordoma

NCT06125171 2023-11-09

Tucidinostat Plus Apatinib for Advanced Osteosarcoma

46 enrolled

Osteosarcoma

NCT03742193 2023-11-01

PROACH

43 enrolled

Phase EARLY_PHASE1 Unknown

Osteosarcoma

NCT04074564 2023-10-23

MASCT-I Combined With Apatinib and/or Camrelizumab in the Treatment of Bone and Soft Tissue Sarcoma

NCT04267549 2023-07-06

Conversion Therapy of Sintilimab in Combination With Apatinib and Chemotherapy in Stage IV Gastric Cancer

47 enrolled

Stomach Neoplasms

NCT05932264 2023-07-06

Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung Cancer

Carcinoma, Non-Small-Cell Lung

NCT04930315 2023-06-13

CAPT

78 enrolled

Carcinoma, Hepatocellular

NCT05853172 2023-05-10

Surgical Conversion of Candonilimab (AK104) Plus Paclitaxel, S-1 and Apatinib for Unresectable Advanced G/GEJ Cancer

30 enrolled

Stomach Neoplasms

NCT04586088 2023-05-06

Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure

58 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT04609176 2023-04-21

Study of Camrelizumab (SHR-1210) and Apatinb Based Therapies for Alpha-fetoprotein (AFP)-Producing Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

64 enrolled

Stomach Neoplasms

NCT04454905 2023-04-19

Camrelizumab in Combination With Apatinib in Advanced ICC: A Single-arm Phase II Study

50 enrolled

Cholangiocarcinoma

NCT05400902 2023-04-13

HAIC Combined With Sintilimab and Bevacizumab for Unresectable Intrahepatic Cholangiocarcinoma

17 enrolled

Cholangiocarcinoma

NCT03048877 2023-04-12

Efficacy of Apatinib in Radioactive Iodine-refractory Differentiated Thyroid Cancer

118 enrolled

EndocrineHead & Neck

Differentiated Thyroid Cancer

NCT04303741 2023-04-12

A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC

46 enrolled

Breast Neoplasms

NCT05556200 2023-04-12

A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILs

58 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT05742750 2023-02-24

A Phase Ib/II Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract Cancer

Phase 1/2 Unknown

48 enrolled

Biliary Tract Neoplasms

NCT05549466 2023-02-08

Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC

84 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT05653817 2022-12-16

Advanced or Metastatic Cholangiocarcinoma

Cholangiocarcinoma

NCT04459078 2022-12-02

Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma

63 enrolled

Adenocarcinoma of Lung

NCT05559008 2022-11-09

A Umbrella Study in R/R PTCL Guided by Molecular Subtypes

Phase 1/2 Unknown

116 enrolled

Lymphoid

Lymphoma, T-Cell, Peripheral

NCT05597527 2022-10-28

Fluzopari Combined With Apatinib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer

35 enrolled

Gynecologic

Ovarian Neoplasms

NCT04012827 2022-09-07

Apatinib Mesylate Combined With Doxorubicin and Ifosfamide in Advanced Soft-tissue Sarcoma

108 enrolled

NCT04749394 2022-08-16

A Study of Camrelizumab Plus Apatinib as Consolidation Therapy in Non-Small Cell Lung Cancer Patients Treated With Chemoradiotherapy

42 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung

NCT03805399 2022-08-10

FUTURE

Phase 1/2 Unknown

140 enrolled

Triple Negative Breast Neoplasms

NCT05290116 2022-08-05

HAIC Combined With Tislelizumab and Apatinib for Unresectable Intrahepatic Cholangiocarcinoma

17 enrolled

Cholangiocarcinoma

NCT05380986 2022-05-19

Camrelizumab Combined With Apatinib Mesylate

500 enrolled

Other solid neoplasm

Solid Tumor

NCT04878107 2022-05-02

SABRE

88 enrolled

Carcinoma, Non-Small-Cell Lung

NCT04229615 2022-04-25

A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy

690 enrolled

Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT05342389 2022-04-22

Camrelizumab Combined With Apatinib Versus Apatinib Alone in the Third-line Treatment of Metastatic Gastric Cancer

68 enrolled

Metastatic Gastric Adenocarcinoma

NCT05216237 2022-04-11

A Study to Evaluate the Efficacy and Safety of Sintilimab Plus Apatinib and Chemotherapy in Patients With HER-2 Negative Microsatellite Stability (MSS) Advanced or Metastatic Gastric (GC) or Gastroesophageal Junction (GEJ) Cancer

31 enrolled

Stomach Neoplasms

NCT05265793 2022-03-04

Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or Carcinosarcoma

45 enrolled

Carcinoma, Carcinosarcoma

NCT03801200 2022-02-08

Apatinib Combined With Radiotherapy in Patient With BM From Drive Gene Negative NSCLC

90 enrolled

CNS

Brain Neoplasms

NCT05225844 2022-02-07

An Exploratory Trail of Camrelizumab Plus Apatinib Mesylate for Advanced Gastrointestinal

150 enrolled

Gastrointestinal Neoplasms

NCT05171309 2021-12-28

Camrelizumab in Combination With Apatinib Plus NK Cell for Advanced HCC

35 enrolled

Carcinoma, Hepatocellular

NCT04901754 2021-12-08

CAMERA

38 enrolled

Small Cell Lung Carcinoma

NCT05095636 2021-10-27

Apatinib Monotherapy Versus Apatinib Combined With Camrelizumab for Third-line Treatment of Metastatic Gastric Cancer

102 enrolled

Neoplasm Metastasis, Stomach Neoplasms

NCT04974944 2021-10-01

First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical Cancer

172 enrolled

Gynecologic

Uterine Cervical Neoplasms

NCT04006821 2021-09-30

PD-1 Antibody + Apatinib Mesylate in 2+ Line Serum AFP-elevated Gastric Adenocarcinoma

30 enrolled

Stomach Neoplasms

NCT05049681 2021-09-20

Study of Anti-PD-1 Antibody SHR-1210 Plus Apatinib vs SHR-1210 as Second-Line Treatment of Advanced Esophageal Squamous Cell

234 enrolled

Esophageal Neoplasms

NCT04724226 2021-09-05

C-couple

34 enrolled

Carcinoma, Hepatocellular

NCT05029453 2021-08-31

Apatinib Combined With Chemotherapy Versus Chemotherapy in Second-line Gastric Cancer Receiving Prior Anti-PD-1 Therapy

Phase 4 Unknown

Stomach Neoplasms

NCT05001412 2021-08-12

Chemotherapy Combined With Camrelizumab and Apatinib in First-line Treatment of ES-SCLC

Phase 1 Unknown

36 enrolled

Extensive Stage Small Cell Lung Cancer

NCT04968002 2021-07-20

Application of Pablizumab Combined With Apatinib and Chemotherapy in Resectable Non-small Cell Lung Cancer： A Prospective, Single Arm, Single Center Phase II Clinical Study of Neoadjuvant Therapy

Phase 2/3 Unknown

40 enrolled

Carcinoma, Non-Small-Cell Lung

NCT03580395 2021-07-09

Apatinib in Neoadjuvant Therapy for Patients With Breast Cancer

Phase 2/3 Unknown

200 enrolled

Breast Neoplasms

NCT04950400 2021-07-06

A Study of Camrelizumab Combined With Chemotherapy Sequential Camrelizumab Combined With Apatinib Treatment of Advanced NSCLC

Carcinoma, Non-Small-Cell Lung

NCT04934618 2021-06-22

A Phase II Study of Carelizumab Combined With Irinotecan and Apatinib of Second-line Treatment for Advanced Gastric Cancer

85 enrolled

Stomach Neoplasms

NCT04781686 2021-05-17

Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer

35 enrolled